Novartis Pediatric Post-Market Plans For Xolair Fall Short Of FDA Request

A post-market program designed by Novartis to control Xolair (omalizumab) in the 6-11 pediatric population was not adequate to convince FDA or its Pulmonary-Allergy Drugs Advisory Committee to extend the indication for use in moderate to severe allergy/asthma patients below 12 years of age

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet